- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05253417
The CANabidiol Use for RElief of Short Term Insomnia (CANREST)
August 13, 2023 updated by: Bod Australia
The CANabidiol Use for RElief of Short Term Insomnia (CAN-REST). A Randomised, Double-Blind, Placebo-Controlled Clinical Study
This study aims to investigate the effect of 50 mg and 100 mg per day oral CBD product versus a placebo over 8 weeks on insomnia severity in adults aged 18-65 years old with insomnia symptoms.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is a double-blind, randomised, parallel-group, placebo-controlled study of 8 weeks of oral CBD at 50 or 100 mg per day versus placebo in 198 participants with insomnia symptoms as classified by an Insomnia Severity Index (ISI) score of 8-21.
Participants will be recruited voluntarily and are able to withdraw at any time.
The study will be conducted online with telehealth consults where required.
Study Type
Interventional
Enrollment (Actual)
208
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New South Wales
-
Glebe, New South Wales, Australia, 2037
- Woolcock Institute
-
-
South Australia
-
Adelaide, South Australia, Australia, 5000
- Fusion Clinical Research
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Male and females aged 18-65 years old, inclusive.
- Females must be non-pregnant, non-lactating.
- Proficient in English and have internet access and a mobile phone.
- Insomnia symptoms as classified by an Insomnia Severity Index (ISI) score of 8 - 21 and have experienced these symptoms over the past month at pre-screening.
- Stated willingness to comply with all study procedures and availability for the duration of the study.
- Provision of signed and dated informed consent form.
- All male and females of childbearing potential must agree to use two forms of effective contraception from the time of signing informed consent until 30 days after study completion.
Exclusion Criteria:
- Serious medical and/or psychiatric illnesses/disorders that will require treatment during the trial period.
The use of any drug known to affect sleep during the study one week prior the randomization, including:
- Sedatives (benzodiazepines, Z drugs, agomelatine, suvorexant, sodium oxybate, sedating antidepressants, sedating antihistamines, antipsychotics, melatonin, valerian).
- Opioids (e.g. morphine, codeine, oxycodone, methadone, buprenorphine, fentanyl, tramadol, tapentadol, hydromorphone).
- Stimulants (e.g. methylphenidate, dexamphetamine, modafinil, phentermine).
- Excessive caffeine use (defined as > 600mg caffeine or approximately 6 cups of caffeinated beverages a day) that, in the opinion of the medical doctor, contributes to the participant's insomnia.
- Excessive alcohol use (defined as per NHMRC guideline, i.e. no more than four standard drinks per day on average for men, and for women, no more than two).
- The use of cannabinoids or a cannabinoid-based medicine within 3 months prior to study Day 1 and unwillingness to abstain from recreational drug use during the study period.
- Cannabis dependence or any other drug or alcohol dependence within the past two years.
- Positive urine drug screen (e.g., amphetamines type substances, benzodiazepines, cannabinoids, cocaine, and opiates) at screening or Day -1 or a history of drug abuse within the past 2 years.
- Known hypersensitivity to cannabis-based products or any of the excipients in the study drug.
- Use of any investigational drug or involvement in another clinical trial within 30 days of screening day.
- Use of anti-coagulant drugs such as warfarin or those known to be metabolised by CYP450 enzymes.
- Current or ongoing treatments for insomnia (e.g. cognitive-behavioural therapy (CBT) and CNS-active drugs).
- Obstructive sleep apnoea determined by the MAPI questionnaire or other self-reported sleep disorders.
- Medical conditions that result in frequent sleep disturbance (e.g. nocturia).
- History of attempted suicide in the past 12 months.
- Clinically significant hepatic abnormalities determined by the screening blood test.
- Shift work, jet lag or trans-meridian travel (two time zones) in the past month.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 50 mg CBD
50 mg CBD to be administered as a single oral dose.
Each capsule contains 25 mg CBD.
Two capsules to be taken (plus two placebo capsules)
|
For the study arm, '50 mg CBD' participants take two (2) CBD capsules and two (2) placebo capsules.
Other Names:
Participants take four (4) placebo capsules.
For the study arm, '100 mg CBD' participants take four (4) CBD capsules.
Other Names:
|
Experimental: 100 mg CBD
100 mg CBD to be administered as a single oral dose.
Each capsule contains 25 mg CBD.
Four capsules to be taken.
|
For the study arm, '50 mg CBD' participants take two (2) CBD capsules and two (2) placebo capsules.
Other Names:
For the study arm, '100 mg CBD' participants take four (4) CBD capsules.
Other Names:
|
Placebo Comparator: Placebo
Placebo capsules contain no CBD.
Four capsules to be taken as a single oral dose.
|
Participants take four (4) placebo capsules.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To investigate the effect of the administration of a 50mg and 100mg per day oral CBD product versus placebo over 8 weeks on insomnia severity index scores
Time Frame: Baseline (week 0), week 4, week 8
|
Insomnia Severity Index (ISI): A 7-item tool measuring the nature, severity, and impact of insomnia over the past 2 weeks.
Each item uses a 5-point Likert scale to capture a rating (0 = no problem; 4 = very severe problem) which add up to: no insomnia (0 - 7); sub-threshold insomnia (8 - 14); moderate insomnia (15 - 21); and severe insomnia (22 - 28).
|
Baseline (week 0), week 4, week 8
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To determine the effect of 8 weeks of 50mg or 100mg of CBD compared to placebo on Anxiety as assessed by the DASS-21 questionnaire.
Time Frame: Baseline (week 0), Week 4, week 8
|
Depression Anxiety Stress Scale-21 (DASS-21): A 21-item tool with subscales measuring the negative emotional states of depression, anxiety, and stress separately.
Depression ranges from normal (0-9) to extremely severe (28+); anxiety ranges from normal (0-7) to extremely severe (20+); and stress ranges from normal (0-14) to extremely severe (34+).
|
Baseline (week 0), Week 4, week 8
|
To determine the effect of 8 weeks of 50mg or 100mg of CBD compared to placebo on wake after sleep onset (WASO) as assessed by actigraphy.
Time Frame: Baseline (week 0), week 8
|
WASO is a parameter that examines the total amount of minutes awake after the first sleep epoch is achieved.
Therefore, as the WASO increases, sleep efficiency decreases.
|
Baseline (week 0), week 8
|
To determine the effect of 8 weeks of 50mg or 100mg of CBD compared to placebo on Stress as assessed by the DASS-21 questionnaire.
Time Frame: Baseline (week 0), Week 4, week 8
|
Depression Anxiety Stress Scale-21 (DASS-21): A 21-item tool with subscales measuring the negative emotional states of depression, anxiety, and stress separately.
Depression ranges from normal (0-9) to extremely severe (28+); anxiety ranges from normal (0-7) to extremely severe (20+); and stress ranges from normal (0-14) to extremely severe (34+).
|
Baseline (week 0), Week 4, week 8
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To determine the effect of 8 weeks of 50mg or 100mg of CBD compared to placebo on Sleep onset latency (SOL) measured by actigraphy.
Time Frame: Baseline (week 0), week 8
|
Sleep onset latency (SOL) is the time it takes to transition from wakefulness to non-REM sleep.
On average, the SOL should take between 10-20 minutes.
Short sleep latencies usually reflect increased sleepiness.
|
Baseline (week 0), week 8
|
To determine the effect of 8 weeks of 50mg or 100mg of CBD compared to placebo on Subjective sleep-related quality of life as assessed by the Functional Outcomes Sleep Questionnaire (FOSQ-10).
Time Frame: Baseline (week 0), week 4, week 8
|
FOSQ-10 is a 10 items questionnaire to measure the impact of daytime sleepiness on activities of daily living.
The score range is 5-20 points, with higher scores indicating better functional status.
|
Baseline (week 0), week 4, week 8
|
To determine the effect of 8 weeks of 50mg or 100mg of CBD compared to placebo on Fatigue assessed by the Flinders Fatigue Scale;
Time Frame: Baseline (week 0), week 4, week 8
|
The Flinders Fatigue Scale is a 7 items self-report scale which assess fatigue over the past 2 weeks.
This scale provides a total fatigue score ranging from 0 to 31, with higher scores indicating greater fatigue.
|
Baseline (week 0), week 4, week 8
|
To determine the effect of 8 weeks of 50mg or 100mg of CBD compared to placebo on Health-related quality of life (HRQoL) assessed using the EQ-5D-5L.
Time Frame: Baseline (week 0), week 4, week 8
|
A descriptive system for health-related quality of life states in adults, consisting of five dimensions.
Each of which has five severity levels that are described by statements appropriate to that dimension.
Those are rated by a verbal 5-point rating scale allowing for distinction of five levels ('5L') of severity: Level 1: no problems; Level 2: slight problems; Level 3: moderate problems; Level 4: severe problems; Level 5: extreme problems per dimension and providing a 1-digit number for each dimension.
|
Baseline (week 0), week 4, week 8
|
To determine the effect of 8 weeks of 50mg or 100mg of CBD on the number of participants with treatment-emergent adverse events
Time Frame: Week 4, Week 8, Week 12
|
The safety and tolerability of the investigational product will be determined by evaluating all incidences of treatment-emergent adverse events as assessed by reported by participants or observed by the investigators or from the safety pathology tests.
|
Week 4, Week 8, Week 12
|
To determine the effect of 8 weeks of 50mg or 100mg of CBD compared to placebo on subjective sleep as assessed by sleep diaries
Time Frame: Baseline (week 0), week 4, week 8
|
Participants will be requested to complete a short, 5-minute online sleep diary for seven mornings to describe the previous night's sleep at baseline, week 4 and week 8.
|
Baseline (week 0), week 4, week 8
|
To determine the effect of 8 weeks of 50mg or 100mg of CBD compared to placebo on self-perception of improvement in sleep as assessed by a self-report questionnaire.
Time Frame: Baseline (week 0), week 4, week 8
|
The self-report questionnaire will ask participants to rate their self-perceived improvement in sleep using a standard 10-point visual analogue scale at weeks 4 and 8
|
Baseline (week 0), week 4, week 8
|
To determine relationship between efficacy endpoint and systemic concentrations of CBD and its carboxy and hydroxy metabolites
Time Frame: Baseline (week 0), week 8
|
Systemic concentrations of CBD (ng/mL), 7- hydroxycannabidiol (7-OH-CBD) (ng/mL) and 7- carboxycannabidiol (7- COOH-CBD) (ng/mL) will be analysed in plasma and urine samples collected at baseline and week 8.
|
Baseline (week 0), week 8
|
To determine the effect of 8 weeks of 50mg or 100mg of CBD compared to placebo on Depression as assessed by the DASS-21 questionnaire.
Time Frame: Baseline (week 0), Week 4, week 8
|
Depression Anxiety Stress Scale-21 (DASS-21): A 21-item tool with subscales measuring the negative emotional states of depression, anxiety, and stress separately.
Depression ranges from normal (0-9) to extremely severe (28+); anxiety ranges from normal (0-7) to extremely severe (20+); and stress ranges from normal (0-14) to extremely severe (34+).
|
Baseline (week 0), Week 4, week 8
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Ron Grunstein, Woolcock Institute of Medical Research
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 1, 2022
Primary Completion (Actual)
July 7, 2023
Study Completion (Actual)
July 7, 2023
Study Registration Dates
First Submitted
December 20, 2021
First Submitted That Met QC Criteria
February 22, 2022
First Posted (Actual)
February 23, 2022
Study Record Updates
Last Update Posted (Actual)
August 16, 2023
Last Update Submitted That Met QC Criteria
August 13, 2023
Last Verified
August 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BOD202101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Insomnia
-
Leiden UniversityBioClock Consortium; Caring UniveristiesCompleted
-
National Science Council, TaiwanCompleted
-
Sunshine Lake Pharma Co., Ltd.Unknown
-
Pfizer's Upjohn has merged with Mylan to form Viatris...Completed
-
Massachusetts General HospitalNational Institutes of Health (NIH)Completed
-
IpsenCompletedThe Effectiveness of Circadin in Improving Quality of Sleep in Patients Aged 55 or Over (QUALISLEEP)InsomniaRussian Federation
-
Charite University, Berlin, GermanyCompleted
-
Roxane LaboratoriesCompleted
-
Butler HospitalSunovionCompleted
Clinical Trials on 50 mg Cannabidiol (CBD)
-
University of California, Los AngelesNot yet recruitingTobacco Smoking | Tobacco Use Disorder | Tobacco DependenceUnited States
-
Zealand University HospitalUniversity of CopenhagenActive, not recruitingChemotherapy-induced Peripheral NeuropathyDenmark
-
Colorado State UniversityCompletedPharmacokinetics | Metabolism | Liver FunctionUnited States
-
West Virginia UniversityCompletedCognitive Impairment | Mood | Sedation Complication | Driving PerformanceUnited States
-
National Institute on Drug Abuse (NIDA)Completed
-
University of California, Los AngelesNational Institute on Drug Abuse (NIDA)CompletedOpioid-use DisorderUnited States
-
University of NebraskaUniversity of Texas at Austin; Ananda Scientific IncRecruiting
-
University of Northern ColoradoCompleted
-
Pure GreenCompletedMusculoskeletal PainUnited States
-
NextEvo Inc.Atlantia Food Clinical TrialsCompletedImmune System Diseases | Immune System and Related DisordersUnited States